कंपनी का अवलोकन
Carlsmed, Inc. operates as a commercial-stage medical technology firm dedicated to designing, manufacturing, and marketing AI-enabled personalized solutions specifically for spine surgery procedures. The company develops the aprevo platform, which serves as a comprehensive technology system for spine fusion surgery, integrating proprietary surgical tools to enhance procedural precision. This entity functions within the Healthcare sector, specifically classified under the Health Information Services industry, positioning it at the intersection of advanced technology and medical necessity. With a market capitalization of $259.83M, annual revenue of $50.51M, and a workforce of 127 employees, Carlsmed occupies a niche position in the specialized medical device market. These valuation and revenue figures suggest the company is in a growth-oriented phase where significant capital investment in research and development is likely driving expansion rather than immediate profitability. The scale of operations, indicated by the current market cap relative to revenue, points to a business model that prioritizes long-term technological adoption in the spine surgery domain over short-term earnings generation.
वित्तीय स्वास्थ्य
Carlsmed, Inc. reported a trailing twelve-month revenue of $50.51M, yet it recorded a net income of $-30,218,000 and an EBITDA of $-30,293,000. The substantial gap between the $50.51M revenue and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by R&D costs, manufacturing overhead, and sales initiatives typical of a commercial-stage technology company. The company generated negative free cash flow of $-21,646,500, indicating that capital expenditures and working capital requirements currently exceed the cash generated from operations. This negative cash flow profile limits immediate financial flexibility for discretionary spending, suggesting a reliance on existing cash reserves or external financing to fund ongoing business activities. The gross margin stands at 75.3%, which indicates strong pricing power or high-value proprietary technology relative to the cost of goods sold. However, the operating margin is significantly lower at -61.4%, and the profit margin is -58.7%, highlighting that high fixed costs and operational inefficiencies are consuming the majority of gross profits before reaching the bottom line. On the balance sheet, the company holds $109.79M in cash against $17.41M in debt, supported by a debt-to-equity ratio of 17.61 and a current ratio of 8.87. Despite the high debt-to-equity figure, the robust current ratio indicates strong short-term liquidity, as the company possesses ample current assets to cover its current liabilities without immediate distress. Conversely, the return on equity is -47.6% and the return on assets is -21.0%, metrics that reveal that management effectiveness is currently constrained by losses rather than value creation, as the company is burning capital to scale its technology platform.
मूल्यांकन आकलन
Carlsmed, Inc. presents a trailing P/E ratio of N/A due to its lack of earnings, while the forward P/E is listed at -6.55. The existence of a negative forward P/E implies that analysts or market participants are projecting continued negative earnings in the near future, or the metric is calculated based on expected losses rather than traditional earnings multiples. The price-to-book ratio is 2.62, suggesting that the market values the company at a premium of 2.62 times its tangible book value, potentially reflecting confidence in its intellectual property and future growth potential despite current losses. The price-to-sales ratio stands at 5.14, which is a high multiple indicating that investors are willing to pay a significant portion of annual sales for a share, a common characteristic of high-growth technology firms. Additionally, the EV/EBITDA ratio is -5.53, further confirming that traditional earnings-based valuation metrics are not applicable due to the negative EBITDA, and valuation is instead driven by revenue growth and asset quality. The stock has traded between a 52-week low of $8.87 and a 52-week high of $17.19. Based on the provided data points, the current price relative to this range cannot be precisely calculated without the specific current share price, but the range itself demonstrates a trading band of approximately 93% between the low and high. The beta value is listed as N/A, meaning there is no calculated measure of the stock's volatility relative to the broader market index available in the provided facts to assess risk exposure.
Growth & Income
Carlsmed, Inc. demonstrated a revenue growth rate of 61.2% year-over-year, while the earnings growth rate is N/A due to negative earnings. The absence of positive earnings growth compared to robust revenue expansion implies that the company is reinvesting all available resources into scaling operations, R&D, and market penetration rather than generating immediate profit. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders. This strategy aligns with the company's current financial position, where earnings are negative, making a dividend payout unsustainable and inappropriate for capital preservation. Instead of paying dividends, the company retains earnings and utilizes its cash reserves to fuel its growth trajectory in the competitive spine surgery technology sector. The overall growth and income profile for Carlsmed is defined by rapid top-line expansion and a complete absence of current profitability or dividend distribution, characteristic of a capital-intensive medical technology firm in its commercialization phase.